Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening

BACKGROUND: Low-dose CT (LDCT) screening trials have shown that lung cancer early detection saves lives. However, a better stratification of the screening population is still needed. In this respect, we generated and prospectively validated a plasma miRNA signature classifier (MSC) able to categoriz...

Descripción completa

Detalles Bibliográficos
Autores principales: Fortunato, Orazio, Huber, Veronica, Segale, Miriam, Cova, Agata, Vallacchi, Viviana, Squarcina, Paola, Rivoltini, Licia, Suatoni, Paola, Sozzi, Gabriella, Pastorino, Ugo, Boeri, Mattia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627262/
https://www.ncbi.nlm.nih.gov/pubmed/36112827
http://dx.doi.org/10.1158/1055-9965.EPI-22-0689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627262/
https://www.ncbi.nlm.nih.gov/pubmed/36112827
http://dx.doi.org/10.1158/1055-9965.EPI-22-0689

Ejemplares similares